These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8398282)

  • 1. Hormone priming in breast cancer: oestrogen priming has a detrimental effect on response in oestrogen receptor-negative patients.
    Seymour L; Meyer K; Bezwoda WR
    Eur J Cancer; 1993; 29A(10):1495-6. PubMed ID: 8398282
    [No Abstract]   [Full Text] [Related]  

  • 2. First-line chemotherapy of advanced breast cancer with mitoxantrone, cyclophosphamide and vincristine.
    Bezwoda WR; Dansey R; Seymour L
    Oncology; 1989; 46(4):208-11. PubMed ID: 2740063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy with or without high-dose medroxyprogesterone acetate in oestrogen-receptor-negative advanced breast cancer. Norwegian Breast Cancer Group.
    Gundersen S; Kvinnsland S; Klepp O; Lund E; Hannisdal E; Høst H
    Eur J Cancer; 1992; 28(2-3):390-4. PubMed ID: 1534248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk stratification for high-dose chemotherapy in metastatic breast cancer.
    Subar M
    J Clin Oncol; 1996 Feb; 14(2):686-7. PubMed ID: 8636796
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of mitoxantrone-based combination chemotherapy regimens as first-line treatment for advanced breast cancer.
    Bezwoda WR; Hesdorffer CS; Dansey RD
    S Afr Med J; 1987 Oct; 72(7):465-7. PubMed ID: 3660150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can patients' likelihood of benefiting from primary chemotherapy for breast cancer be predicted before commencement of treatment?
    Ogston KN; Miller ID; Schofield AC; Spyrantis A; Pavlidou E; Sarkar TK; Hutcheon AW; Payne S; Heys SD
    Breast Cancer Res Treat; 2004 Jul; 86(2):181-9. PubMed ID: 15319570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitoxantrone combined with vincristine, cyclophosphamide and fluorouracil for advanced breast cancer. A study of short-term response rate.
    Misset JL; Metz R; Gil-Delgado M; Keiling R; Cappelaere P; Armand JP; Prévot G; Grimbert J; Mathé G; Hibberd M
    Anticancer Res; 1987; 7(4B):737-40. PubMed ID: 3674760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose chemotherapy for breast cancer.
    Spiridonidis CH; Laufman LR; Rhodes V; Jones J
    J Clin Oncol; 1996 Feb; 14(2):686. PubMed ID: 8636795
    [No Abstract]   [Full Text] [Related]  

  • 9. Mitoxantrone for advanced breast cancer.
    Gupta P; Tandon R
    J Assoc Physicians India; 1992 Apr; 40(4):282. PubMed ID: 1452548
    [No Abstract]   [Full Text] [Related]  

  • 10. Randomized trial of cyclophosphamide, methotrexate, and 5-fluorouracil with or without estrogenic recruitment in women with metastatic breast cancer.
    Ingle JN; Foley JF; Mailliard JA; Krook JE; Hartmann LC; Jung SH; Veeder MH; Gesme DH; Hatfield AK; Goldberg RM
    Cancer; 1994 May; 73(9):2337-43. PubMed ID: 8168039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial of chemotherapy and hormonal therapy in advanced breast cancer.
    Kiang DT; Gay J; Goldman A; Kennedy BJ
    N Engl J Med; 1985 Nov; 313(20):1241-6. PubMed ID: 3903501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of anti-oestrogen Zitazonium (tamoxifen) as adjuvant to cytostatic treatment in metastatic breast cancer.
    Palka I; Jávor J
    Ther Hung; 1986; 34(4):217-23. PubMed ID: 3449976
    [No Abstract]   [Full Text] [Related]  

  • 13. High-dose chemotherapy (CTM) for breast cancer.
    Damon LE; Wolf JL; Rugo HS; Gold E; Zander AR; Cassidy M; Cecchi G; Cohen N; Irwin D; Tracy M; Ries CA; Linker CA
    Bone Marrow Transplant; 2000 Aug; 26(3):257-68. PubMed ID: 10967563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer.
    Holmes FA; Yap HY; Esparza L; Buzdar AU; Hortobagyi GN; Blumenschein GR
    Semin Oncol; 1984 Sep; 11(3 Suppl 1):28-31. PubMed ID: 6385262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical effects of combination therapy with mitoxantrone, vincristine, and prednisolone in breast cancer.
    Katsumata K; Tomioka H; Kusama M; Aoki T; Koyanagi Y
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):86-8. PubMed ID: 12764670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of LHRH agonists in premenopausal women with oestrogen receptor-positive breast cancer: the ZEBRA experience.
    Jonat W
    Eur J Cancer; 2002 Nov; 38 Suppl 6():S39-40. PubMed ID: 12409069
    [No Abstract]   [Full Text] [Related]  

  • 17. [Rational combinations of hormonal and cytostatic agents in disseminated forms of breast cancer].
    Garin AM; Dmitrieva NV; Vyshinskaia GV; Lichintser MR
    Vopr Onkol; 1987; 33(11):13-7. PubMed ID: 3686916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of time to response to chemotherapy in 316 metastatic breast cancer patients.
    Pronzato P; Bertelli G; Gardin G; Rubagotti A; Conte PF; Rosso R
    Oncology; 1993; 50(6):460-5. PubMed ID: 8233288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of mitoxantrone in the treatment of breast cancer.
    Hainsworth JD
    Semin Oncol; 1995 Feb; 22(1 Suppl 1):17-20. PubMed ID: 7863347
    [No Abstract]   [Full Text] [Related]  

  • 20. The use of mitoxantrone plus cyclophosphamide as first-line treatment of metastatic breast cancer.
    Bezwoda WR; Hesdorffer C
    Cancer; 1986 Oct; 58(8):1621-4. PubMed ID: 3756786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.